CAJ | 학술논문

目的：评价TACE术联合EOF方案系统治疗中晚期原发性肝癌的疗效和不良反应°方法 A组为对照组,32例,单纯行肝动脉化学栓塞术° B组为治疗组,26例,肝动脉化学栓塞术2次后行EOF方案全身静脉化疗,直到病情进展或不适宜继续治疗及出现不可耐受的不良反应° B组肝动脉栓塞术后4~6周开始行EOF方案化疗,即：吡柔比星40 mg/m2 d1,澳沙利铂OXA 85 mg/m2 d~1.8,5-FU 0.5g/m2 d1~5°28 d为1个周期,连用2个周期后评价疗效°结果A、B两组的总有效率(RR率﹚为37.5%vs61.5%,疾病控制率(DCR率﹚为84.39%vs96.1%,1年生存率50%vs88.4%,2年生存率18.7%vs61.5%,3年生存率12.5%vs19%°主要不良反应为骨髓抑制, IV°不良反应少见°结论TACE术联合EOF方案系统治疗中晚期原发性肝癌能显著提高有效率和1年、2年的生存率,不良反应可以耐受,依从性高,可作为中晚期原发性肝癌的一种有效的治疗模式°
목적：평개TACE술연합EOF방안계통치료중만기원발성간암적료효화불량반응°방법 A조위대조조,32례,단순행간동맥화학전새술° B조위치료조,26례,간동맥화학전새술2차후행EOF방안전신정맥화료,직도병정진전혹불괄의계속치료급출현불가내수적불량반응° B조간동맥전새술후4~6주개시행EOF방안화료,즉：필유비성40 mg/m2 d1,오사리박OXA 85 mg/m2 d~1.8,5-FU 0.5g/m2 d1~5°28 d위1개주기,련용2개주기후평개료효°결과A、B량조적총유효솔(RR솔﹚위37.5%vs61.5%,질병공제솔(DCR솔﹚위84.39%vs96.1%,1년생존솔50%vs88.4%,2년생존솔18.7%vs61.5%,3년생존솔12.5%vs19%°주요불량반응위골수억제, IV°불량반응소견°결론TACE술연합EOF방안계통치료중만기원발성간암능현저제고유효솔화1년、2년적생존솔,불량반응가이내수,의종성고,가작위중만기원발성간암적일충유효적치료모식°
Objective To evaluate the treatment efficacy and toxicity of advanced primary liver cancer under the systemic treat_ment of TACE combined with EOF regimen. Methods Transcatheter arterial chemoembolization was given to 32 cases in group A (control group). Systemic venous chemotherapy with EOF regimen was given to 26 cases in group B(treatment group) after they un_derwent transcatheter arterial chemoembolization for 2 times until the disease progressed or the patients were not appropriate to continue the treatment or the toxicity was intolerable. 4-6 weeks after transcatheter arterial chemoembolization, group B began to undergo chemotherapy with EOF regimen, namely, the detailed regimen is pirarubicin 40 mg/m2 d1, oxaliplatin (OXA) 85 mg/m2 d1-8, 5-FU 0.5 g/m2 d1-5. The evaluation of treatment efficacy should be given after 2 continuous circles based on 28 days per circle. Results The overall response rate (RR) in group A is lower than that in group B (37.5% VS 61.5%), disease control rate (DCR) is lower than that in group B(84.39%VS 96.1%), 1-year survival rate is lower than that in group B(50%VS 88.4%), 2-year survival rate is lower than that in group B (18.7%VS 61.5%), 3-year survival rate is lower than that in group B (12.5%VS 19%). The primary toxic side effect is bone marrow suppression, IV° adverse reactions are seldom reflected. Conclusion For advanced primary liver cancer, systemic treatment of TACE combined with EOF regimen can obviously improve the efficacy and 1-year and 2-year survival rate with tolerable side effects and high compliance. It could be an effective treatment pattern for advanced prima_ry liver cancer.